According to the Zhitong Finance APP, Hualan Vac (301207.SZ) released its performance forecast for 2024, expecting a net profit attributable to shareholders of the listed company to be between 200 million and 250 million yuan, a year-on-year decrease of 70.93% to 76.74%.

Reasons for the performance change: In order to improve the accessibility of influenza vaccines, enhance product market competitiveness and market share, and alleviate the economic burden on the public and the government while fulfilling corporate social responsibility, the company adjusted the price of its quadrivalent influenza vaccine product in June 2024 based on market conditions, with the prices of major products reduced by more than 40%. In 2024, the company's business development and profitability were significantly impacted by multiple factors such as changes in public vaccination rates, a decline in vaccine market demand, and reduced sales, leading to a significant decline in the company's performance for the year.

The company has always adhered to an innovative positioning and high-quality development, continuously maintaining investment in the research and development of innovative vaccines, genetic engineering vaccines, and other technological platforms; it has also increased research and development exploration for product innovation, clinical product transformation, and registration efforts. The R&D expenses have remained at a high level, which has had a certain adverse impact on the company's net profit.

For 2024, the company expects the impact of non-recurring gains and losses on net profit to be approximately 90 million yuan, mainly due to investment income generated from idle funds